Thyroid Eye Disease: Multidisciplinary Management of Treatment-Associated Hearing Loss (Online CME Monograph)
Activity Description and Purpose
This educational activity is intended to help clinicians evaluate real-world data pertaining to hearing dysfunction associated with thyroid eye disease treatment with the insulin-like growth factor 1 receptor antagonist teprotumumab. Clinicians will learn how to implement optimal strategies for monitoring and managing hearing loss in patients treated with teprotumumab. The desired results of this activity are for clinicians to use a multidisciplinary approach to increase their ability to identify and manage hearing loss in patients who require treatment of thyroid eye disease.
This educational activity is intended for ophthalmologists, oculoplastic surgeons, and neuro-ophthalmologists.
After completing this activity, participants will be better able to:
- Evaluate key and impactful real-world data pertaining to hearing dysfunction associated with thyroid eye disease treatment
- Implement optimal strategies for monitoring and managing hearing loss in patients treated with insulin-like growth factor 1 receptor antagonists for thyroid eye disease
Prem S. Subramanian, MD, PhD (Chair)
Jennifer Alyono, MD, MS
César A. Briceño, MD
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity. All relevant relationships have been mitigated.
Jennifer Alyono, MD, MS, is a contracted researcher for Astellas Pharma US, Inc,* and Cochlear Ltd.
César A. Briceño, MD, is an advisory board member of Amgen Inc, F. Hoffmann-La Roche Ltd, and Genentech, Inc.
Prem S. Subramanian, MD, PhD, is a consultant for Acelyrin, Inc; is an advisory board member of Amgen, GenSight Biologics, Kriya Therapeutics, and Viridian Therapeutics, Inc; and is a contracted researcher for Immunovant, Inc, Invex Therapeutics*, Neurophth Therapeutics, and Tourmaline Bio, Inc.
Hadi Kaakour, MD, was formerly an advisory board member of Alimera Sciences*.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
* The financial relationship existed during the past 24 months but has now ended
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Amgen Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs or devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Amgen Inc.
This CME activity is copyrighted to MedEdicus LLC ©2023. All rights reserved. 308
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation